The study is a prospective, randomized, non-blinded, national, multi-center study. The study will consist of the assignment of eligible patients to treatment with either a HeartMate III (HM III) left ventricular assist device system or to pharmacological treatment (optimal medical management, OMM) according to current guidelines. One hundred and forty (140) patients will be enrolled in this study and randomized in a 1:1 fashion between the HM III and OMM.